Citizens Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 92.5%

Neg 0% Neu 0% Pos 92.5%

Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and raises the price target from $8 to $11.